Operating Income (Loss) in USD of Terns Pharmaceuticals, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Terns Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q1 2020 to Q3 2025.
  • Terns Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$27.7M, a 11.1% decline year-over-year.
  • Terns Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$108M, a 8.5% decline year-over-year.
  • Terns Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$102M, a 0.67% increase from 2023.
  • Terns Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$103M, a 65.3% decline from 2022.
  • Terns Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$62M, a 24.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Terns Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$108M -$27.7M -$2.78M -11.1% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$106M -$27.4M -$1.85M -7.23% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 -$104M -$27.4M -$1.98M -7.79% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 -$102M -$25.9M -$1.89M -7.86% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-20
Q3 2024 -$100M -$24.9M +$8.25M +24.8% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$108M -$25.5M -$4.38M -20.7% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 -$104M -$25.4M -$1.29M -5.34% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 -$103M -$24.1M -$7.23M -43% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-20
Q3 2023 -$95.3M -$33.2M -$15.9M -91.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$79.4M -$21.2M -$7.08M -50.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$72.4M -$24.2M -$10.3M -74.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$62M -$16.8M -$2.95M -21.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$59.1M -$17.3M -$5.42M -45.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$53.7M -$14.1M -$3.27M -30.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$50.4M -$13.8M -$529K -3.98% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$49.9M -$13.9M -$5.11M -58.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 -$44.8M -$11.9M -$3.13M -35.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$41.6M -$10.8M -$721K -7.14% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$40.9M -$13.3M -$3.87M -41.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$37M -$8.77M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-07
Q3 2020 -$8.74M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$10.1M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$9.42M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14

Terns Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$102M +$687K +0.67% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-20
2023 -$103M -$40.5M -65.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-20
2022 -$62M -$12.2M -24.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$49.9M -$12.8M -34.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-27
2020 -$37M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.